Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 91 AL 105

Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature

Lathe R, Sapronova A, Kotelevtsev Y.

BMC Geriatr. 2014 Mar 21;14:36. doi: 10.1186/1471-2318-14-36.

Pharmacotherapies for sleep disturbances in Alzheimer's disease

McCleery J, Cohen DA, Sharpley AL.

Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178. doi: 10.1002/14651858.CD009178.pub2.

Considering a new paradigm for Alzheimer's disease research

Langley GR.

Drug Discov Today. 2014 Aug;19(8):1114-24. doi: 10.1016/j.drudis.2014.03.013. Epub 2014 Mar 21.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.

Brain metabolite clearance: impact on Alzheimer's disease

Zolezzi JM, Inestrosa NC.

Metab Brain Dis. 2014 Sep;29(3):553-61. doi: 10.1007/s11011-014-9527-2. Epub 2014 Mar 25.

Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?

Persson T, Popescu BO, Cedazo-Minguez A.

Oxid Med Cell Longev. 2014;2014:427318. doi: 10.1155/2014/427318. Epub 2014 Jan 5.

Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets

Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L.

J Alzheimers Dis. 2014;42 Suppl 3:S177-87. doi: 10.3233/JAD-132621.

Formulations: friendly, fast, forgiving and flexible

Citrome L.

Int J Clin Pract. 2014 Apr;68(4):407. doi: 10.1111/ijcp.12420.

Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL

Nardone R, Höller Y, Thomschewski A, Kunz AB, Lochner P, Golaszewski S, Trinka E, Brigo F.

J Neural Transm (Vienna). 2014 Oct;121(10):1313-20. doi: 10.1007/s00702-014-1195-1. Epub 2014 Mar 28.

Type 3 diabetes mellitus. The revival of inhaled insulin?

Formiga F, Pérez-Maraver M.

Endocrinol Nutr. 2014 Apr;61(4):173-5. doi: 10.1016/j.endonu.2014.03.001.

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease

Beauchet O, Launay CP, Allali G, Herrmann FR, Annweiler C.

Drugs Aging. 2014 May;31(5):363-72. doi: 10.1007/s40266-014-0175-3.

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

Ghosh AK, Osswald HL.

Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h.

A new regulatory road-map for Alzheimer's disease drug development

Becker RE, Greig NH.

Curr Alzheimer Res. 2014 Mar;11(3):215-20. doi: 10.2174/156720501103140329210642.

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2014 Apr 29;82(17):1536-42. doi: 10.1212/WNL.0000000000000364. Epub 2014 Apr 2.

Investigational drugs in Alzheimer's disease: current progress

Berk C, Paul G, Sabbagh M.

Expert Opin Investig Drugs. 2014 Jun;23(6):837-46. doi: 10.1517/13543784.2014.905542. Epub 2014 Apr 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias